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Abstract
The kallikreins and kallikrein-related peptidases are serine
proteases that control a plethora of developmental and home-
ostatic phenomena, ranging from semen liquefaction to skin
desquamation and blood pressure. The diversity of roles
played by kallikreins has stimulated considerable interest in
these enzymes from the perspective of diagnostics and drug
design. Kallikreins already have well-established credentials
as targets for therapeutic intervention and there is increasing
appreciation of their potential both as biomarkers and as tar-
gets for inhibitor design. Here, we explore the current status
of naturally occurring kallikrein protease-inhibitor complex-
es and illustrate how this knowledge can interface with strat-
egies for rational re-engineering of bioscaffolds and design
of small-molecule inhibitors.
Keywords: bioscaffold; drug design; inhibitor; phage
display; protease positional scanning synthetic
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Introduction
The kallikrein peptidase family
The extended kallikrein peptidases are defined by homology
to either of two ancestral serine proteases, plasma kallikrein
or tissue kallikrein, which differ in their gene location,
sequence and structure. Whereas plasma kallikrein (KLKB1,
located at 4q34-q35) has no related homologue, the tissue
kallikrein-related peptidases (KLKs) form a highly conserved
multi-gene locus encoding enzymes with either trypsin- or
chymotrypsin-like activity (Yousef and Diamandis, 2001;
Clements et al., 2004). Fifteen KLKs have been characterised
to date, arranged as a tandemly clustered array on chromo-
some 19q13.3-13.4 (Clements et al., 2004). This represents
the largest known continuous collection of proteases within
the human genome (Puente et al., 2003).
Typically, KLK proteins are produced according to strict
temporal and spatial expression patterns and function in reg-
ulated activation cascades, suggesting an involvement in a
diverse range of physiological processes (Pampalakis and
Sotiropoulou, 2007). Both liver-derived KLKB1 and tissue-
derived KLK1, as well as KLK2 and KLK12 in vitro (Giusti
et al., 2005), participate in the progressive activation of
bradykinin, a bioactive peptide involved in blood pressure
homeostasis and inflammation initiation (Bhoola et al.,
1992). Although this is the only demonstration of classical
kininogenic activity that was the original hallmark of kallik-
rein proteases, the contribution of subsets of KLKs to vital
physiological processes is well appreciated. Prostate-
expressed KLK2, 3, 4, 5 and 14 are involved in seminogelin
hydrolysis (Lilja, 1985; Deperthes et al., 1996; Takayama et
al., 2001b; Michael et al., 2006; Emami and Diamandis,
2008), KLK6 and 8 have reported functions in defining neu-
ral plasticity (Shimizu et al., 1998; Scarisbrick et al., 2002;
Tamura et al., 2006; Ishikawa et al., 2008) and KLK5, 7, 8
and 14 assist in epidermal remodelling via controlled pro-
teolysis of corneodesmosomal proteins (Caubet et al., 2004;
Brattsand et al., 2005; Stefansson et al., 2006; Kishibe et al.,
2007). These kallikrein-driven phenomena are critical pro-
cesses within the prostate, central nervous system and skin,
respectively.
In parallel to identification of the kallikrein locus (and
serine proteases generally), attempts have been made to pro-
duce inhibitors to regulate these enzymes and thus maintain
the delicate homeostatic balance between degradation
and synthesis in crucial biological pathways. It has been un-
equivocally shown that failure of inhibition in kallikrein-
related pathways causes detrimental effects that in turn have
led to a burgeoning interest in the design and synthesis of
kallikrein-specific inhibitors.
Kallikrein structure
Collectively, the KLKs exhibit a number of structural and
functional similarities that need to be considered and can be
exploited in targeted inhibitor design. All tissue KLK genes
consist of five exons of almost identical size with intermit-
tent introns displaying a fully conserved phase (Yousef and
Diamandis, 2001). This has consequences in terms of trans-
lated protease sequence; each KLK contains the conserved
serine protease catalytic triad (His57, Asp102, Ser195) and
N-terminal regulatory pre- and pro- sequences, meaning that
KLKs are expressed as inactive precursors (zymogens).
Although the sequence homology within the classical KLK
cluster (KLK1–3) is markedly higher (62–72%) than simi-
larities with any of the more recently characterised KLKs
(25–49%) (Harvey et al., 2000), emerging crystallographic
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Figure 1 Structural alignment of KLK1–15, KLKB1 and b-trypsin.
(A) Ribbon plot of KLK1 (PDB accession no. 1SPJ) as a representative KLK structure. b-Sheets and a-helices are shown in yellow and
blue, respectively, with important features highlighted in green and purple, with catalytic residues displayed as stick models. (B) Sequence
similarity between KLK1–15 and KLKB1 mapped onto the surface of b-trypsin with conservation visualised as a gradient from blue (high),
cyan, green and light green to yellow (low). The alignment was produced in Swiss-PdbViewer 4.0.1 using the KLK1, 3-7, KLKB1 and b-
trypsin crystal structures (PDB accession nos. 1SPJ, 2ANY, 2ZCH, 2BDH, 2PSX, 1L2E and 2QXI, 1SFI) and KLK2 and 8–15 models
created using Swiss Model (Guex et al., 2009). (C) Structural alignment of sequence conservation between KLK1–15, KLKB1 and b-
trypsin. Location of b-sheets and a-helices are indicated by yellow arrows and blue cylinders, respectively, with catalytic residues shown
in cyan. Important features are highlighted in green and purple and cysteine residues participating in disulfide bonds are shown in yellow.
Completely conserved residues and conservative substitutions are shown in dark grey and light grey, respectively.
studies have revealed that KLK tertiary structure across the
locus is highly conserved (Figure 1). Indeed, the kallikrein
‘molecular chassis’ conforms to the canonical trypsin fold,
consisting of an almost entirely b-sheet arrangement (SCOP
trypsin-like serine proteases; SCOP ID 50493). Furthermore,
although the KLKB1 gene encodes four additional N-terminal
domains, its level of sequence similarity across the catalytic
domain is not dissimilar to that observed for the tissue KLK
locus (Figure 1).
Rationale for kallikrein inhibition
Consistent with the important role of kallikrein proteases in
normal physiology, defective control of expression or activity
is strongly linked to development of disease. Most prominent
is the potential significance of KLKs to certain cancers typ-
ified by aberrant KLK expression including lung, pancreatic,
colon (Yousef et al., 2004) and hormone-dependent cancers,
particularly those of the prostate (Magklara et al., 2000;
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Petraki et al., 2003; Veveris-Lowe et al., 2005), ovaries
(Dong et al., 2001; Yousef et al., 2003; Prezas et al., 2006)
and breast (Yousef et al., 2002; Zhang et al., 2006; Pampa-
lakis et al., 2009). Contrasting effects of KLK overexpres-
sion on cancer physiology have been proposed. KLK
overexpression can provide a pathway for tumour develop-
ment and metastasis by degrading the restrictive localised
tissue architecture and shifting the cellular signalling axis to
drive increased proliferation. Alternatively, differential KLK
expression can have a protective function in certain cancers.
A considerable amount of research has been devoted to
exploring the utility of KLK panels as hormone-dependent
cancer biomarkers (Borgono and Diamandis, 2004; Clements
et al., 2004). KLK3 (prostate-specific antigen, PSA) remains
the gold-standard biomarker for prostate cancer diagnosis
and prognosis (Stamey et al., 1987; Catalona et al., 1991),
albeit with some degree of controversy.
In the context of the skin, a role for KLKs has been iden-
tified in the rare but severe disorder Netherton syndrome
(OMIM: 256500) (Chavanas et al., 2000; Descargues et al.,
2005; Briot et al., 2009), as well as the milder but much
more frequent condition acne rosacea (Yamasaki et al., 2007;
Stefansson et al., 2008). Furthermore, KLK1 and KLKB1
have been implicated in a number of diseases associated with
dysregulation of the kallikrein/kinin system, such as cardio-
vascular, renal, inflammatory and gastrointestinal tract dis-
ease (Devani et al., 2002; Stadnicki et al., 2003). Finally,
KLK6 and KLK8 have potential roles in neurodegenerative
conditions such as Alzheimer’s disease (Little et al., 1997;
Shimizu-Okabe et al., 2001), multiple sclerosis (Terayama et
al., 2005; Scarisbrick et al., 2008), epilepsy (Momota et al.,
1998), synucleinopathies (Iwata et al., 2003) and general
central nervous system inflammation (Blaber et al., 2004).
The identification of dysfunctional KLK activity as a major
pathological influence suggests that targeted inhibition of rel-
evant KLKs is likely to be an effective therapeutic strategy.
Transient inhibition of certain kallikrein-mediated pro-
cesses has already been explored and the use of aprotinin to
reduce peri-operative bleeding in cardiac surgery by inhib-
iting proteases involved in haemostatic and inflammatory
processes was widespread (Fritz and Wunderer, 1983; Terrell
et al., 1996). Although initially thought to be successful, this
therapy has recently been withdrawn from use following the
result of several larger clinical trials that were terminated
before completion because of a persistent trend of increased
mortality (Murkin, 2009). Since this outcome is very recent,
the probable physiological explanation is yet to be deter-
mined, although one might speculate that it involves inter-
ference with unrelated biological pathways owing to the
broad range activity of aprotinin, much like the first-gener-
ation matrix metalloprotease (MMP) inhibitors.
Naturally occurring kallikrein inhibitors
Although proteases drive numerous vital physiological pro-
cesses, activity must be tightly regulated to ensure correct
spatial and temporal delivery. The function of mature pro-
teases is commonly controlled by protein-based inhibitors
that adopt the form of a non-hydrolysable substrate. Whereas
almost all inhibitors bind to their cognate protease via an
exposed motif, the mechanism by which they achieve inhi-
bition varies from canonical inhibitors that simply block the
protease active site to serpins that irreversibly disturb the
delicate conformation of the protease (Laskowski and Kato,
1980). A number of canonical and serpin inhibitors of KLK
proteases have been identified. These include physiological
inhibitors that provide an essential regulatory influence on
KLK-mediated processes and activation cascades, as well as
broad-range, exogenous inhibitors that function as valuable
research tools for determining the significance of KLK activ-
ity in experimental systems. Notable KLK inhibitors are dis-
cussed in more detail below and a comprehensive inhibitory
profile of natural and engineered inhibitors is provided in
Figure 2A–D.
Canonical inhibitors
Standard-mechanism or canonical inhibitors currently form
the largest class of protein-based inhibitors. Here, protease
inhibition generally involves contact with the target protease
via the canonical loop, a characteristic exposed binding motif
on the inhibitor surface that is complementary to the active-
site cleft. This interaction is often referred to as analogous
to the formation of a protease-substrate complex, since both
are non-covalent, tight-binding and reversible with contact
occurring across extended b-sheets (Tyndall et al., 2005).
However, in the protease-inhibitor complex, hydrolysis of the
reactive-site P1-P19 peptide bond is rare, preventing subse-
quent dissociation of the complex and temporarily removing
the ability of the protease to bind substrate (Laskowski and
Kato, 1980). The importance of this binding mechanism is
highlighted by the fact that the conformation of the canonical
loop is very similar, even among diverse families of protease
inhibitors (Figure 2E).
Kunitz-domain inhibitors
Canonical inhibitors of this class are characterised by the
Kunitz domain, a motif spanning 50–60 residues that con-
tains the inhibitory binding loop within a central anti-parallel
b-sheet (Figure 2E). Considerable rigidity across the domain
is imparted by a network of conserved disulfide bonds
(Hynes et al., 1990; Perona et al., 1993). Most prominent is
bovine pancreatic trypsin inhibitor (BPTI), also previously
referred to as kallikrein inactivator, aprotinin or trasylol. Fol-
lowing isolation and crystallisation from bovine pancreatic
tissue extracts, biochemical characterisation revealed that
BPTI was a potent inhibitor of not only bovine trypsin, but
also KLKB1 (Kraut et al., 1930). Later studies that extended
to the classical tissue kallikrein locus reported inhibitory
activity against KLK1 (Hofmann and Geiger, 1983) and
KLK2 (Geiger et al., 1980). More recently, BPTI/aprotinin
has been widely used as a non-specific reagent to block the
activity of kallikrein proteases in vitro, including KLK7
(Lundstrom and Egelrud, 1988), KLK5 and 14 (Brattsand et
al., 2005), and KLK2 and 4 (Mize et al., 2008).
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BPTI has no homologue expressed in humans and there-
fore is not an endogenous modulator of kallikrein proteases,
but several potent inhibitors of KLKB1 and KLK1 have been
isolated from human tissue, including tissue factor pathway
inhibitor-2 (TFPI-2) (Petersen et al., 1996) and Kunitz-type
protease inhibitor domains from Alzheimer amyloid precur-
sor protein (APP) and its homologue APPH (Petersen et al.,
1994). A further KLKB1 and KLK1 inhibitor, serine pepti-
dase inhibitor Kunitz-type 2 (SPINT2) was later isolated
from human placental tissue and termed bikunin because of
its double-headed Kunitz domain structure (Delaria et al.,
1997). Plant material has also proven to be a rich source of
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Figure 2 Comparison of the activity of naturally occurring and engineered kallikrein inhibitors and structural overlay of the conserved
binding loop of protein kallikrein inhibitors.
Representation of the relative kallikrein inhibitory activity for an extensive selection of reported naturally occurring (blue), engineered
protein (orange) and synthetic small-molecule (green) inhibitors. Data were compiled using the reported Ki (canonical inhibitors, panel A
and synthetic inhibitors, panel B), IC50 (metal ions, panel C) or ka (covalent inhibitors, panel D) value for each kallikrein-inhibitor complex.
Importantly, the relative inhibition values encompass different modes of inhibition and, undoubtedly, different experimental conditions, and
therefore solely provide a relative comparison and should not be taken as absolute. Abbreviations: APP(H) KPI, Alzheimer amyloid precursor
protein (homologue) Kunitz protease inhibitor; BbTI, Bauhinia bauhinioides trypsin inhibitor; BfTI, Bauhinia forficata trypsin inhibitor;
BuXI, Bauhinia ungulate factor Xa inhibitor; BvTIp, Bauhinia variegata trypsin inhibitor, purple variety; CeKI, Caesalpinia echinata
kallikrein inhibitor; CMTI, Cucurbita maxima trypsin inhibitor; EcTI, Enterolobium contortisiliquum trypsin inhibitor; LlTI, Leucaena
leucocephala trypsin inhibitor; PAI-1, plasminogen activator inhibitor-1, STI, soybean trypsin inhibitor; SFTI, sunflower trypsin inhibitor;
SLPI, secretory leukocyte protease inhibitor; SwTI, Swartzia pickellii trypsin inhibitor. (E) Overlay of the binding loops from various classes
of naturally occurring kallikrein inhibitors (inhibitor/class/PDB accession number): LEKTI domain 6/Kazal/1HOZ; aprotinin/Kunitz/2FTL;
Barley Bowman-Birk inhibitor/Bowman-Birk inhibitor/1TX6; a1-antitrypsin/Serpin/1OPH; SFTI/Bowman-Birk-like/1SFI; E. coli trypsin
inhibitor/Ecotin/1EZU; bound to the active site of b-trypsin. Trypsin is shown as grey ribbons, with catalytic residues as stick models. The
inhibitors are shown as yellow b-sheets and green coils. Note that all inhibitors interact with the protease via an extended b-sheet (black
arrow).
Kunitz-type compounds that inhibit KLKs; KLKB1 (Oliva
et al., 1999), KLK7 (Lundstrom and Egelrud, 1988), KLK5
and 14 (Brattsand et al., 2005) are inhibited by soybean tryp-
sin inhibitor (SBTI). Inhibition of KLKB1 has also been
demonstrated using novel compounds from Enterolobium,
Leucaena, Swartzia and several Bauhinia species (Sampaio
et al., 1996), as well as Caesalpinia echinata kallikrein inhib-
itor (CeKI) (Cruz-Silva et al., 2004).
Kazal-domain inhibitors
Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is
produced as a multi-domain serine protease inhibitor encod-
ed by the SPINK5 gene (chromosome 5q31-32) (Magert et
al., 1999). Within the skin and thymus, the LEKTI pro-pro-
tein is processed into up to 15 individual subunits. Structur-
ally, the resulting fragments are typified by a Kazal-like
domain arrangement; an anti-parallel b-sheet bordered by
two short a-helices is held together by conserved disulfide
links. Most LEKTI domains carry basic residues (Arg or
Lys) at their putative P1 sites, suggesting that trypsin-like
proteases are likely targets for LEKTI-derived peptides
(Magert et al., 1999). A range of LEKTI fragments can mod-
ulate KLK activity, albeit with differing efficiency; KLK5,
7 and 14 are inhibited by LEKTI D8–11 and LEKTI D5
(Deraison et al., 2007), and KLK5 and 7 are inhibited by
LEKTI D6–99 (Schechter et al., 2005) and LEKTI D6 (Egel-
rud et al., 2005). This activity, in synergy with physiological
factors such as pH, provides an essential regulatory influence
on the cascade of kallikrein proteases associated with
desquamation (Borgono et al., 2007b; Deraison et al., 2007).
An additional SPINK-related product, LEKTI2 encoded by
SPINK9, has recently been identified within the skin and
shows KLK5-specific inhibition restricted to the palmoplan-
tar epidermis (Brattsand et al., 2009; Meyer-Hoffert et al.,
2009).
Other canonical inhibitors
Aside from the classical Kunitz- and Kazal-type inhibitors,
several other prominent canonical inhibitors of KLKs have
been identified. Purified from the periplasm of Escherichia
coli, ecotin is a 32-kDa dimeric serine protease inhibitor with
broad-range activity. Characterisation revealed that it is a
very potent inhibitor of proteases of the contact activation
system, including KLKB1 (Ulmer et al., 1995). Hirustasin,
a serine protease inhibitor isolated from the medical leech
Hirudo medicinalis, contains a single antistasin-like domain
and is a potent inhibitor of KLK1, but not KLKB1 (Sollner
et al., 1994). A detailed investigation of KLK inhibitors iso-
lated and purified from stratum corneum extracts identified
the elafin-like protease inhibitor antileukoprotease as a skin-
expressed KLK7 inhibitor and the potato type-1 inhibitor
eglin C as an exogenous inhibitor (Franzke et al., 1996).
More recently, several KLK inhibitors have been isolated
from plant material; Cucurbita maxima trypsin inhibitor
(CMTI) -I and -II exhibit inhibitory activity against serine
proteases of the clotting cascade, including KLKB1
(Grzesiak et al., 2000a), and sunflower trypsin inhibitor
(SFTI) is a non-specific Bowman-Birk-like inhibitor of
KLK4 (Swedberg et al., 2009).
Serpins
Abundant in circulating human plasma, serpins are large
protein-based inhibitors that irreversibly attenuate the activ-
ity of their target protease. Like canonical inhibitors, contact
with the protease is made via an extended b-sheet (Figure
2E). However, the serpin mechanism of inhibition is unique
in that it is characterised by catalysis of the P1-P19 peptide
bond, which causes both a change in the serpin conformation
and formation of a protease-inhibitor covalent bond (Loe-
bermann et al., 1984). Recent crystallographic studies have
further clarified this phenomenon. Since the protease is tight-
ly linked to the inhibitor, the serpin structural change due to
cleavage at the reactive centre induces a shift in conforma-
tion of the bound protease (Huntington et al., 2000). The
resulting loss of protease structure has terminal effects on
catalytic ability, namely distortion of the catalytic triad via
displacement of Ser195 and collapse of vital interactions
formed during zymogen activation (Huntington et al., 2000).
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Several endogenous serpin KLK inhibitors have been
identified to date. Best characterised are those found in the
circulating plasma, such as a2-macroglobulin, antithrombin
III, a1-antitrypsin, a2-antiplasmin and protein C inhibitor,
which inhibit KLKB1 (Gallimore et al., 1979; Schapira et al.,
1982), KLK2 (particularly protein C inhibitor) (Deperthes
et al., 1995; Frenette et al., 1997) and KLK3 (Christensson
et al., 1990). The search for additional serum-based inhibi-
tors for KLK1 other than a1-antitrypsin (Geiger et al., 1981)
led to the isolation and characterisation of kallistatin, a novel
58-kDa serpin that complexes with KLK1 in vitro more read-
ily than other circulating inhibitors (Zhou et al., 1992). Fur-
thermore, the recently identified interaction between KLK8
and serpin B6 (Scott et al., 2007) is of particular interest
since inhibition of KLK8 by common skin-based inhibitors
(such as LEKTI fragments) is yet to be successfully
achieved. Serpin inhibition of KLK5, 7, 8 and 11–14 has
also been examined in vitro using a1-antitrypsin, a1-antichy-
motrypsin, kallistatin, antithrombin-III, protein C inhibitor,
plasminogen activator inhibitor-1, a2-antiplasmin and C1
inhibitor (Luo and Jiang, 2006).
Divalent ions
Although not strictly defined as protease inhibitors, several
divalent ion species also show an ability to modulate KLK
protease activity. Initially, studies were confined to the clas-
sical KLK cluster and it was demonstrated that prostate-
expressed KLK2 and KLK3 are inhibited by zinc (Lovgren
et al., 1999; Malm et al., 2000). KLK3 is also inhibited by
copper, mercury, cobalt and cadmium ions in vitro, although
the extent of inhibition is considerably weaker (Malm et al.,
2000). More recently, zinc inhibition of KLK4 (Debela et al.,
2006a), KLK5 (Michael et al., 2006; Debela et al., 2007a),
KLK7 (Debela et al., 2007b), KLK8 (Kishi et al., 2006) and
KLK14 (Borgono et al., 2007c) was demonstrated and cor-
responding crystallographic approaches suggest a potential
molecular mechanism for inhibition, at least for certain
KLKs. For both KLK5 and KLK7, metal ion binding is coor-
dinated by exposed His residues (His96 or His99 for KLK5
and His99 for KLK7) (Debela et al., 2007a,b). The bound
divalent ion subsequently interacts with the catalytic His57
residue, displacing it from the active site. KLK4 is subtly
different in that the metal ion binding site is produced by
His25 and Gln77 (Debela et al., 2006a).
Naturally occurring inhibitors have evolved over time to
function in a temporal and spatial manner that elegantly off-
sets their broad-range activity. However, since disease path-
ogenesis is highly complex and can involve partial or even
multiple protease cascades, and since treatments are often
administered systemically, therapeutic inhibition must be
highly specific with low levels of off-target inhibition. This
explains why natural inhibitors, although effective at
regulating key physiological processes, very rarely have
appreciable value as therapeutics. Therefore, the focus has
shifted to engineered inhibitors that can deliver the require
selectivity.
Inhibitor engineering
Design challenges: potency and specificity
Protease inhibitors require high affinity if they are to be suc-
cessful as therapeutic agents. The evolution of HIV-1 pro-
tease inhibitors revealed important design strategies when
analysed from a thermodynamic viewpoint (Freire, 2006).
The affinity of the inhibitor for the protease is determined
by the Gibbs free energy of binding, with enthalpy and entro-
py changes corresponding to different types of atomic inter-
actions (Freire, 2006). The change in enthalpy is proportional
to the strength of binding between the inhibitor and the pro-
tease, such as hydrogen bonds, van der Waals interactions
and salt bridges. However, in aqueous medium the entropy
increases on binding because water molecules are freed from
solvation layers around hydrophobic areas and thus become
less ordered. Therefore, to achieve maximum affinity, hydro-
phobic repulsion from the aqueous medium must be com-
bined with strong inhibitor-protease interactions achieving
favourable entropy and enthalpy. The first-generation HIV-1
protease inhibitors (indinavir, nelfinavir and saquinavir) were
characterised by favourable entropy but unfavourable enthal-
py (Velazquez-Campoy et al., 2001), whereas second-gen-
eration inhibitors exhibited both favourable enthalpy and
entropy with resulting higher affinity (Ohtaka and Freire,
2005). It thus appears that finding a balance between enthal-
pic and entropic changes on inhibitor-protease binding is
vital for high-affinity inhibitors.
The importance of inhibitor selectivity is underlined by
the high profile failure in clinical trials of a series of MMP
inhibitors. These were designed to block MMP-mediated
remodelling of the cellular microenvironment and thus halt
tumour growth and metastasis (Zucker et al., 2000). Unfor-
tunately, the majority have been terminated following Phase
III trials because of a lack of or even negative survival ben-
efits. Critical evaluations of MMPI performance concluded
that this was due, at least in part, to their broad-spectrum
activity (Zucker et al., 2000; Coussens et al., 2002; Overall
and Lopez-Otin, 2002; Turk, 2006). This resulted in blockade
of important off-target cellular processes that were in fact
anti-tumourigenic (Vazquez et al., 1999), as well as activa-
tion of pro-tumorigenic signalling pathways (Maquoi et al.,
2002) or interference with unrelated functions with detri-
mental side effects, such as tendonitis-like musculoskeletal
pain (Giavazzi et al., 1998). Selective inhibitors can be
designed by exploiting unique structural features within the
active site. These can be identified by screening high-affinity
ligands against a panel of the most closely related proteases
to establish selectivity, which, in the case of a KLK, should
include all related tryptic or chymotryptic members of the
family.
Design challenges: mapping the KLK active site
The twin goals of specificity and potency described above
are attainable provided the engineered inhibitor has a com-
pletely complementary fit with the active site of its target
protease. Accordingly, irrespective of the inhibitor being
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Figure 3 Phage-display cycle.
Genetic diversity is generated by ligating degenerate oligonucleo-
tides into the genome of filamentous bacteriophage (typically M13)
to produce fusion proteins with pIII, pV or pVII bacteriophage coat
proteins. The resultant bacteriophage library is then allowed to inter-
act with an immobilised bait molecule (BINDING) after which
weakly bound bacteriophages are removed by washes of increasing
stringency (WASH) prior to harvesting of more specifically bound
bacteriophage particles by cycles of high- and low-pH washing
(ELUTE). The resulting eluate is then reamplified in an E. coli
bacteriophage propagation strain (AMPLIFY) and iteratively
screened and amplified through a further three or four cycles to
produce a final library through pseudo-evolutionary selection. Indi-
vidual clones from this library are then sequenced and validated
through interaction or inhibition assays.
designed, the first step is to probe the active site of the target
enzyme. The most common strategies revolve around map-
ping the active site of the target protease through bacterio-
phage display, positional scanning and sparse matrix
substrate libraries.
Bacteriophage display (or biopanning) exploits the phys-
ical link between peptides on the exterior of the bacterio-
phage particle and the genetic material that carries the code
for it. In its simplest form, phage display parallels natural
evolution, with subpopulations of genetically diverse bacte-
riophage libraries iteratively selected and amplified by bind-
ing to an immobilised target; see Smith and Petrenko (1997)
for a review. This technique has been spectacularly success-
ful as a tool for sampling the chemical landscape of short
peptides and monoclonal antibodies, resulting in a series of
drugs currently available in the clinic, including Avastin,
Rituxan and Lucentis (Dimitrov and Marks, 2009). An
ingenious twist in the application of phage display has refo-
cused this technique as a tool for discovering protease cleav-
age specificities. This strategy turns the affinity maturation
concept on its head so that non-selected sequences are immo-
bilised on a solid support and sequences are selected follow-
ing cleavage from the solid support. This technique, which
was pioneered by Matthews and Wells (1993) revolves
around expression of the bacteriophage pIII protein as a
fusion protein with an affinity tag, with the pIII portion of
the fusion protein being separated from the affinity tag by a
randomised sequence. The resulting bacteriophage library is
then immobilised on an affinity matrix specific for the fusion
partner on the modified pIII protein. Bacteriophages that
have linker sequences that are substrates for a given protease
will be cleaved off the solid support and can be harvested
by filtration and subject to affinity maturation through iter-
ative cycles of amplification, immobilisation and cleavage
(Figure 3). To date, this technology has been applied to
KLKB1 (Dennis et al., 1995), KLK2 (Cloutier et al., 2002),
KLK3 (Coombs et al., 1998), KLK6 (Sharma et al., 2008)
and KLK14 (Felber et al., 2006). These studies in turn guid-
ed the design of the engineered bioscaffolds discussed below.
The strength of phage display lies in the magnitude and
diversity of the libraries that can be screened. However, the
screening technique itself is not without inherent bias and
blind spots. In particular, pIII fusion peptides have the poten-
tial to modulate bacteriophage infectivity. In turn, this can
lead to under- or over-representation of particular sequences
during screening through their ability to propagate during
reamplification rather than by virtue of their affinity for an
immobilised ligand (Wilson and Finlay, 1998). Peptide
sequences can also be strongly selected by the solid support
used for immobilisation of the target protease. Immobilised
metal affinity chromatography (IMAC) is notorious for its
ability to select for pIII fusion proteins with multiple histi-
dine residues. These issues are highlighted by studies by
Cloutier et al. (2002) that identified peptide substrates for
KLK2 using phage display. Although a number of substrates
for the enzyme were identified, none of these achieved the
catalytic efficiency of the control substrate (TFRSA), nor
was this sequence selected. However, this may reflect the
fact that assays were based on peptide hydrolysis whereas
selection was carried out on the basis of protein cleavage.
Selection bias inherent in biological libraries is circum-
vented by the positional scanning synthetic combinatorial
library (PS-SCL) approach, which uses solid-phase chemis-
try to generate diversity. It consists of sub-libraries of pep-
tides for each binding subsite of the protease; thus, if the
P1–P4 sites are to be investigated, four sub-libraries are
needed. These contain 20 pools of peptides, each with a dif-
ferent fixed amino acid for that protease subsite (P1, P2, P3
or P4), whereas the other positions have a mixture of all
amino acids (Dooley and Houghten, 1993). By screening the
rate of proteolysis against all 80 pools, the individual con-
tribution of each amino acid at each subsite to substrate rec-
ognition or inhibitor binding is revealed. Positional scanning
has been used to probe the active site of a number of KLKs;
the outcomes are summarised in Table 1.
Although this information is invaluable, it is important
when interpreting PS-SCL data to be conscious of the
assumptions on which the method is based. First, it is
assumed that the contributions of each position to biological
activity are independent of each other. One argument against
this is what can be termed P-site overlap: although the results
from the screen indicate that the same residue is favoured in
adjacent positions, when assayed as an individual peptide,
this is not the case. Two PS-SCL studies of KLK4 ranked
Gln favourably for the P2 and P3 positions (Matsumura et
al., 2005; Debela et al., 2006b), whereas assays of individ-
ually synthesised peptides revealed that Gln is only favoured
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Table 1 Extended substrate specificity of KLK1–15 and KLKB1.
P1 P2 P3 P4 Method Reference
KLKB1 R n/a n/a n/a PDL Dennis et al., 1995
KLK1 F/K/Y L/F n/a n/a PDL Li et al., 2008
KLK2 R H/L/R n/a n/a Peptides Janssen et al., 2004
KLK3 M)n)A L)A/M/Q)n Y)V)M/n/I V)M/A/Q)T PS-SCL Debela et al., 2006b
KLK4 R)K Q)T/L)V)P V)Q)T)S/A F)I)V)Y/W SML Swedberg et al., 2009
KLK5 R S)A/N/T)P M)Y)K/F/n G)Y)V/P/W PS-SCL Debela et al., 2006b
KLK6 R)A/n/M R)K A)K/S/Y/M V)Y/I/M/G PS-SCL Debela et al., 2006b
KLK7 Y)A/M/n Y)L)T/F/n T/M)H/A/V K/Q/M/V PS-SCL Debela et al., 2006b
KLK8 R/K n/a n/a n/a Peptides Rajapakse et al., 2005
KLK9 n/a n/a n/a n/a n/a n/a
KLK10 R)K/n/M D)E/R)K/M E/D)S/Y/M M)D/E/V/n PS-SCL Debela et al., 2006b
KLK11 M)n)K/R)A R)K/D)E)S D/E/M)Y)S M)D/E/V/M PS-SCL Debela et al., 2006b
KLK12 K)R n/a n/a n/a Peptides Memari et al., 2007
KLK13 R)N N)L)F)Y/A R V)Y)I/P/G PS-SCL Borgono et al., 2007a
KLK14 R N/A)P)H/S K/A)R/S/n Y)W)F/V/I PS-SCL Borgono et al., 2007a
KLK15 R n/a n/a n/a Peptide Takayama et al., 2001a
Amino acids are shown in one-letter code, with ‘n’ representing norleucine. Bold font indicates the most preferred residue at each
subsite. When several sources of data were available, selections were made according to the following priority order: Sparse Matrix
Library (SML), Positional Scanning Synthetic Combinatorial Library (PS-SCL), Phage Display Library (PDL) and peptides. n/a, not
applicable.
at these subsites if one but not both Gln are present (Swed-
berg et al., 2009). This suggests that the residue interacts
with an area of the protease accessible from both subsites.
Another misconception is that PS-SCL results can be uni-
versally applied to protein substrates. A PS-SCL study of
KLK3 revealed a strong preference for Met at the P1 site
(Table 1), although comparison with known cleavage sites
for protein substrates indicates that Tyr and Gln are preferred
(Merops database, http://merops.sanger.ac.uk/). An inspec-
tion of the S1 pocket of the KLK3 structure suggests that it
is too narrow to fit Tyr or Gln, but not Met. Therefore, it
may well be that binding of a larger protein substrate, which
occurs over a considerably larger surface area, causes an
induced fit and enables access to larger residues such as Tyr
and Gln.
A final inherent problem of the PS-SCL method is the
assumption that all amino acid couplings occur with the same
efficiency. Considering the popularity of the PS-SCL meth-
od, it is surprising that very few examinations of differential
reaction rates in mixtures of amino acids have been made.
Early solid-phase experiments noted differential reaction
rates (Bayer and Hagenmaier, 1968; Ragnarsson et al., 1971,
1974; Sandberg and Ragnarsson, 1974) and compensation
methods were later used to solve this problem (Kramer et
al., 1993; Ostresh et al., 1994; Ivanetich and Santi, 1996).
This issue has been highlighted by Boutin et al. (1997), who
found ten-fold variations in concentration between different
sequences and an absence of 35% of all theoretical sequen-
ces. These findings may explain why two PS-SCL (Matsu-
mura et al., 2005; Debela et al., 2006b) screens did not detect
the strong preference of KLK4 for Phe at P4 (Swedberg et
al., 2009).
To overcome these problems, positional preferences sug-
gested by PS-SCL can be verified by screening against a
sparse matrix library, a small sub-library of individually syn-
thesised and verified peptides (typically 50–200 members)
selected from the PS-SCL (Swedberg et al., 2009). This strat-
egy is complementary to the positional scanning approach,
but circumvents the problems of subsite cooperativity and
incomplete and under-represented sequences. In addition,
since each peptide is individually assayed, there is often far
greater selectivity apparent for each position in the peptide.
Design challenges: bioavailability and stability
For protease inhibitors to be viable therapeutic agents, they
must be not only potent and specific towards their target
protease, but also readily bioavailable (Fear et al., 2007). The
bioavailability of a drug in a particular tissue is governed by
its ability to cross biological barriers to reach the site versus
its rate of degradation and excretion. Orally bioavailable
drugs in humans commonly fulfil Lipinski’s rule of five,
which states that the compound should contain not more than
five hydrogen bond donors or ten acceptors, an octanol-water
partition coefficient of less than five and a molecular mass
below 500 Da (Lipinski et al., 2001). Conversely, the poten-
cy of inhibition depends on the number and nature of contact
points between the protease and inhibitor, whereas specificity
relies on their uniqueness. Therefore, the design of potent,
specific and bioavailable KLK inhibitors represents quite a
challenge, especially considering the high level of conser-
vation among the KLKs described earlier (Figure 1).
Methods that both reduce enzymatic degradation and renal
clearance of peptide and protein drugs include polysialyla-
tion and PEGylation, in which polysialic acid or poly
(ethylene glycol) is attached to one or both termini of the
peptide/protein. Polysialylation is a natural strategy to
improve peptide and protein half-life (Jain et al., 2004) and
was recently used to increase the in vivo availability of an
antitumour monoclonal antibody (H17E2 Fab fragment) by
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a factor of five (Constantinou et al., 2008). PEGylation is
approved by the FDA as a vehicle for pharmaceuticals
(Harris and Chess, 2003) and is used in a number of protein-
based drugs currently on the market (Veronese and Harris,
2008) with an annual market value of over $US4 billion
(Krishan, 2007).
Peptide-based inhibitors particularly suffer from short
half-lives since they are often hydrophilic and thus show
poor oral absorption and are rapidly cleared by the kidneys
(Werle and Bernkop-Schnurch, 2006). In addition, peptide
drugs are often quickly degraded by the numerous exo- and
endo-proteases present in most tissues (Werle and Bernkop-
Schnurch, 2006). Even if intravenously administered, most
peptides are cleared from the bloodstream within minutes.
To overcome these particular challenges, peptide lead com-
pounds often need to be modified in various ways, depending
on the route of administration and the target tissue. N- and
C-terminal modifications such as N-acetylation and C-ami-
dation can reduce degradation by exoproteases (McGregor,
2008). For example, the natural peptide thymopoietin
involved in T-cell maturation has a half-life of 1 min in plas-
ma, whereas a double end-capped version shows no detect-
able degradation (Heavner et al., 1986). Similarly, capping
with fatty acids can improve both the half-life and lipophi-
licity of a peptide, a technique used to improve serum
stability of an anti-proliferative somatostatin analogue (Das-
gupta et al., 2002).
Backbone- and/or disulfide bond-circularised peptides are
intrinsically stable to degradation, a common feature in nat-
urally occurring peptides. A diverse range of plants produce
cyclotides, circular miniproteins with a cysteine knot of three
intertwined disulfides, believed to be involved in host
defence (Craik et al., 2002; Gruber et al., 2008). Many bac-
teria also produce circular peptides (bacteriocins) to target
competing species (Mercedes et al., 2008), as do many
marine microorganisms (Hamada and Shioiri, 2005). This
approach was recently used by Clark et al. (2005) to produce
a backbone-cyclised snail venom peptide (a-conotoxin)
analogue with improved stability in serum.
A more significant challenge is to improve peptide resis-
tance to endoprotease activity, since this involves peptide
backbone and/or side chain modifications that are likely to
have major effects on inhibitor potency and specificity. One
strategy involves the substitution of certain amino acids that
are known to be targets of proteolysis with non-natural D-
amino acids, as has been used to produce a variety of pro-
tease-resistant reagents including small peptides (Silvia et al.,
2008) and antibodies (Webb et al., 2005). Alternatively, sub-
stitution of peptide backbone atoms, in particular participants
of the amide bond, can be used to produce what are com-
monly referred to as pseudopeptides. For example, the amide
nitrogens of scissile bonds can be methylated (N-methyla-
tion) to prevent hydrolysis, as for the fungal peptide immuno-
suppressant cyclosporine A. This peptide has seven N-meth-
ylations, as well as one D-amino acid, and is highly bioa-
vailable since it is chiefly degraded by the hepatic
cytochrome P450 3A enzyme system rather than by prote-
ases (Dunn et al., 2001). Recent advances in methods for
synthesis of multi N-methylated peptides (Biron et al., 2006)
have yielded a somatostatin analogue with four-fold higher
half-life after oral administration (Biron et al., 2008). A num-
ber of less commonly used amide bond surrogates also exist,
including retro bonds (NH-CO), carba bonds (CH2CH2), aza
bonds (CO-NH-NR-CO), reduced amide (CH2NH) and urea
bonds (HN-CO-NH). These have previously been reviewed
elsewhere (Adessi and Soto, 2002; Lozano et al., 2006).
Curiously, certain naturally occurring small protein inhib-
itors that deviate from Lipinski’s rule of five are readily bio-
available. For example, orally administrated Bowman-Birk
inhibitors (;8 kDa) are readily bioavailable (Kennedy,
1998) and the same is true for cyclotides (;3 kDa), at least
in insects (Whetstone and Hammock, 2007). There is a grow-
ing realisation that many of the issues above can be solved
at a stroke by using naturally occurring inhibitors of serine
proteases. For example, the inhibitors aprotinin (Terrell et al.,
1996) and hirudin (Zeymer, 1998) have seen clinical use as
modulators of bleeding after thoracic surgery and thrombo-
lysis, respectively. The obvious next step for these naturally
occurring inhibitors is to produce variants with redirected
inhibitory specificity and enhanced potency. Use of these
bioscaffolds is becoming increasingly common as their
advantages in terms of stability, specificity and potency are
recognised.
Engineered inhibitors: bioscaffolding
Bioscaffolding revolves around the use of natural template
structures (bioscaffolds) in contrast to more conventional
small-molecule approaches. Extensive use is made of pre-
existing natural protease inhibitors, which are re-engineered
using recombinant DNA techniques or solid-phase peptide
synthesis. The chief features of successful bioscaffolds are a
structure that is both robust and flexible enough to tolerate
multiple amino acid substitutions, and a template structure
that has intrinsic protease inhibitor activity. Thus, the engi-
neering goal is simply to redirect and enhance existing
inhibitory activity. Further advantages come from facile pro-
duction of inhibitor molecules in living systems, thus facil-
itating biopanning (phage display) and cheap and efficient
large-scale bioproduction in microbial or plant systems.
Currently there are four classes of bioscaffold with rele-
vance to kallikreins: serpins, Kunitz-domain inhibitors, eco-
tin and SFTI derivatives. All four classes of inhibitor interact
with their target proteases through the canonical loop
described above (Tyndall et al., 2005; Figure 2E), forming
an extension of the protease b-sheet structure. However, the
scaffolding presenting the reactive loop shows considerable
structural diversity and plays varying roles in stabilising the
protease-inhibitor complex. In addition to these four estab-
lished bioscaffolds, there is also a move towards production
of specific monoclonal antibodies that can inhibit kallikreins,
with Dyax developing a specific KLK1 inhibitor for treat-
ment of asthma (Sexton et al., 2009). This antibody was
selected from a so-called Fab-on-phage library (Steukers et
al., 2006), which contains genes encoding the antibody
366 J.E. Swedberg et al.
Article in press - uncorrected proof
heavy- and light-chain variable regions that are then
displayed on the phage surface as Fabs and selected using
surface plasmon resonance screening. Other non-clinical
examples include antibody-mediated inhibition of KLK13 in
a cell-based model of extracellular matrix degradation
(Kapadia et al., 2004) and use in biochemical characterisa-
tion of KLK12 (Memari et al., 2007). Both the bioscaffold
and monoclonal antibody approaches make extensive use of
phage display as a primary design tool. However, bioscaffold
design is also driven by information from positional scanning
and sparse matrix libraries, as outlined below.
Serpins
To date, three serpins have been exploited as bioscaffolds;
C1-inhibitor protein, which inhibits the complement system
(Kase and Pospisil, 1983); human a1-antitrypsin (AAT),
which protects lung tissue from the effects of human neutro-
phil elastase (Sun and Yang, 2004); and human a1-antichy-
motrypsin (ACT), which is associated with the development
of Alzheimer’s disease (Potter et al., 2001). All three inhib-
itors are high-molecular-weight ()50 kDa) plasma proteins
that contact their target proteases via a canonical loop, which
is termed a reactive loop since it is cut by the target protease.
Although the reactive loop does in theory control the major-
ity of the specificity of a given serpin, there is also a signif-
icant contribution from serpin exosites such that swapping
reactive loops alone between serpin subtypes is not sufficient
to completely redirect their inhibitory activity (Djie et al.,
1997). Nonetheless, the reactive loop is very tolerant of sub-
stitution and this has led to the development of a series of
recombinant kallikrein inhibitors.
Initially, an inhibitor for KLKB1 was developed using a
variant of C1-inhibitor (Sulikowski et al., 2002). C1-inhibitor
effectively blocks KLKB1 activity and the aim of the re-
engineering was to increase the inhibition specificity and
prevent the blockade of other complement proteases. Accord-
ingly, a reactive loop variant was designed on the basis of
the plasma KLK substrate specificity, which was previously
assessed using a relatively small pool of arginine methyl
esters (Levison and Tomalin, 1982). The resulting variant
showed the specificity required and maintained potency, with
ka of 382 180 M-1 s-1. Following this success, a KLK2 inhib-
itor was designed using ACT as bioscaffold (Cloutier et al.,
2004). The ACT reactive loop was substituted with a KLK2-
specific sequence found through phage display (Cloutier
et al., 2002), yielding an inhibitor with a ka value of 6261
M-1 s-1.
More recently, Felber et al. (2006) re-engineered the reac-
tive loop of both AAT and ACT serpins using pentapeptides
derived from a phage display scan against immobilised
KLK14 (Felber et al., 2005). Currently, KLK2 ACT-derived
inhibitors are being developed by Med Discovery, with the
lead compound, MDKP67b, close to entering clinical trials
as a targeted treatment for prostate cancer. The success of
this approach owes much to the adaptability of the serpin
reactive loop. In addition, using a human serpin as a bio-
scaffold, the problem of patient immune response to a protein
therapeutic is neatly avoided.
Kunitz domain
Originally identified in BPTI, the Kunitz-domain inhibitory
motif is remarkably compact and shows considerable thermal
stability (Moses and Hinz, 1983; Makhatadze et al., 1993).
Both BPTI and the Alzheimer’s amyloid b-protein precursor
(APPI), which has a similar structure to BPTI, have been
exploited as bioscaffolds. APPI was the first bioscaffold sub-
jected to phage display. Screening against KLKB1 achieved
a Ki value of 15 pM (Dennis et al., 1995). A later study
searched for potent inhibitors of six distinct serine proteases,
including KLKB1. This study focused on the BPTI canonical
loop, substituting positions P1, P3 and P4 with amino-acid
side chains gauged to explore the diversity of charge, shape
and hydrophobicity. The best inhibitor against KLKB1
showed a ki value of 5.4 nM, a modest 2.2-fold improvement
over the wild-type inhibitor; considerable thermal destabilis-
ation was observed when P4 mutations were undertaken
(Grzesiak et al., 2000b).
The Kunitz-domain approach has also had some success
in the world of commercial drug design and development,
with a Dyax product, ecallantide (DX-88), reaching Phase
III clinical trials for treatment of hereditary angioedema.
Ecallantide was derived from a phage display screen of the
Kunitz domain of human lipoprotein-associated coagulation
inhibitor (LACI) using immobilised KLKB1 as bait. It has a
reported Ki value of 44 pM and is highly specific for KLKB1
(Williams and Baird, 2003). At the time of writing, FDA
approval for use of ecallantide was awaiting completion of
a risk evaluation and mitigation strategy.
Ecotin
Ecotin (E. coli trypsin inhibitor) was isolated from the peri-
plasmic space of E. coli and is a dimeric, bidentate protease
inhibitor (Chung et al., 1983). It is thought to provide pro-
tection against the effects of neutrophil elastase (Eggers et
al., 2004), which it inhibits with a Ki value of 12 pM. Inter-
action between the protease and ecotin is driven by four
loops (two from each ecotin monomer) and results in the
formation of a heterotetramer with a very extensive buried
surface area of 2850 A˚ 2. Interestingly, binding by the contact
loops is not restricted to the trypsin active site, but also
includes residues that are highly divergent within the trypsin
superfamily. Accordingly, these secondary contacts have the
potential to provide greater selectivity than that of inhibitors
that bind at the active site alone. This prompted Craik and
co-workers (Stoop and Craik, 2003) to re-engineer the ecotin
bioscaffold to produce a series of variant molecules that can
inhibit KLKB1, thrombin, MT-SP1 and FXIIa. Two distinct
design strategies were used, a simple progressive substitution
of the ecotin apparent P1 residue and biopanning using phage
display. Ecotin, like the C1-inhbitor bioscaffold, is a potent
inhibitor of KLKB1 but lacks selectivity against other con-
tact activation proteases. Given the role of the contact loops,
as well as the canonical loop, in protease complex formation,
a library of ecotin variants was produced by gene shuffling
to target all five motifs. This library was screened against
immobilised KLKB1 as described above and, in a novel
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Figure 4 Tetrahedral transition-state analogues of serine proteases.
(A) Structure of the P1-P19 residues and adjoining peptide bond on
a typical amide substrate (left) and putative tetrahedral intermediate
formed coordinately with the Ser195 (catalytic) side chain prior to
cleavage of the peptide bond (right). (B) Representation of a boronic
acid inhibitor (e.g., P8720, Figure 2B) (left) and subsequent com-
plex formation via covalent bond formation with the Ser195 (cata-
lytic) hydroxyl group (right). (C) Structure of a peptide aldehyde
inhibitor (e.g., hK2p01, Figure 2B) (left) and covalent bond for-
mation with the Ser195 (catalytic) hydroxyl group (right). (D) Rep-
resentation of a chloromethyl ketone inhibitor (e.g., CH-2856,
Figure 2B) (left) and mechanism of inhibition via dual linkage to
the target protease at Ser195 (catalytic) as well as the adjacent His57
(catalytic) by the exposed CH2-Cl group (right).
deviation from the normal phage display procedure, the
library was pre-blocked with soluble proteases from classes
against which inhibitory activity was to be selected. This led
to the isolation of an ecotin variant with a Ki value for
KLKB1 of 11 pM but with activity against factor Xa, factor
XIa, urokinase-type plasminogen activator thrombin, and
membrane-type serine protease 1 that is four to seven orders
of magnitude lower (Stoop and Craik, 2003).
Sunflower trypsin inhibitor
SFTI belongs to the Bowman-Birk serine protease inhibitor
family and is a potent inhibitor of trypsin, cathepsin G and
suppressor of tumourigenesis (14 ST14/matriptase/MT-SP1).
It was originally discovered in sunflower (Helianthus
annuus) seeds and characterised by determination of its
three-dimensional structure in complex with bovine b-tryp-
sin (Luckett et al., 1999). Consisting of just 14 cyclised ami-
no acids bisected by a disulfide bond, SFTI is intermediate
between the macromolecular scaffolds represented by the
bioscaffolds above and the small-molecule inhibitors
described below. Its smaller size allows for facile chemical
synthesis (Zablotna et al., 2002; Korsinczky et al., 2005) and
rapid generation of variants. In addition, a very recent pub-
lication described expression of a library of fully cyclic SFTI
variants in E. coli (Austin et al., 2009), opening up the pos-
sibility of rapid in vivo screening.
Similar to the other bioscaffolds described above, SFTI
interacts with its target proteases via a canonical-type loop.
However, unlike the larger molecules, SFTI has essentially
no molecular scaffolding behind it, relying on its fully cyclic
backbone and a disulfide bond for stability. Interestingly, the
structure of SFTI is maintained even when the disulfide is
removed (by substituting glycine or aminobutyric acid),
being preserved by an internal hydrogen bond network
(Korsinczky et al., 2005). However, this variant is not stable
to cleavage by proteases. Surprisingly, there have been few
attempts to use the SFTI molecule as a bioscaffold and the
small number of variants produced have not been tested in
cell culture or animal systems. To date, only KLK4 has been
actively targeted; Swedberg et al. (2009) used a sparse matrix
library approach to probe the KLK4 active site, and then
substituted the optimal sequence obtained into the SFTI bio-
scaffold. This strategy improved both the potency and spec-
ificity of KLK4 inhibition by SFTI, increasing its potency
by nearly two orders of magnitude to give a Ki value of
3.6 nM. Moreover, the specificity of inhibition improved to
give 500-fold selectivity against the closely related KLK14.
Thus, in contrast to the situation for serpins described above,
re-engineering of just three residues is sufficient to complete-
ly redirect the inhibitory activity of SFTI. This reflects the
lack of interactions with regions outside the active-site cleft
in the SFTI/protease complex.
Despite the inhibitory potency of these bioscaffolds, only
ecallantide has successfully made the transition to clinical
use. This may reflect the fact that ecotin, Kunitz-domain and
serpin-based inhibitors are all macromolecular inhibitors
requiring intravenous administration. Although the much small-
er SFTI may yet prove to be readily bioavailable, detailed
pharmacokinetics are currently unavailable for either wild-
type or engineered versions of this scaffold. In addition, the
other bioscaffold-based inhibitors show considerable cross-
reactivity between the kallikreins. Clearly there is consider-
able scope for further investigation focused on these
remarkable reagents, which have the potential to become as
successful as the small-molecule approaches conventionally
applied to protease inhibitor design.
Engineered inhibitors: small-molecule inhibitors
The most commonly used small-molecule kallikrein inhibi-
tors are serine protease-specific tetrahedral transition-state
analogues. These include peptides in which the C-terminal
carboxyl acid is substituted for boronic acid, an aldehyde or
halogenated methyl ketones to form a tetrahedral adduct with
Ser 195 (Figure 4). For example, Fareed et al. (1981) used
KLK2 and KLKB1 kininogen cleavage sites to design pep-
tide aldehyde inhibitors with Ki values of 10–20 mM,
although these inhibitors showed little specificity against a
number of serine proteases of the blood clotting cascade. A
boronic acid inhibitor based on a similar peptide sequence
produced a potent (Ki 150 pM) and more specific KLKB1
368 J.E. Swedberg et al.
Article in press - uncorrected proof
inhibitor (Dela Cadena et al., 1995). Concurrently, Evans et
al. (1996a,b) reported conservative non-natural amino acid
substitutions of KLKB1 kininogen cleavage sites combined
with a fluoroalkyloxymethyl ketone functionality to develop
a series of specific KLK1 inhibitors with Ki values in the
lower nM range. These inhibitors attenuated breast cancer
cell invasion in a Matrigel-based model (Wolf et al., 2001).
More recently, the boronic acid approach was used to devel-
op inhibitors to PSA; the best has a Ki value of 65 nM
(LeBeau et al., 2008). However, there are limited specificity
data available for these compounds and their biological
impact is ambiguous.
Using a different strategy, Wanaka et al. (1990) capped
phenylalanine N-terminally with benzylamine to yield a
competitive KLKB1 inhibitor (Ki 810 nM). This strategy, pre-
viously used to produce trypsin, plasmin and thrombin inhib-
itors (Markwardt et al., 1968), capitalises on mimicking the
P1 arginine by the benzylamine group; the ‘peptide bond’ is
displaced, resulting in a non-hydrolysable compound. Vari-
ous derivatives of this compound were later screened to
produce a more potent KLKB1 inhibitor with a Ki value of
130 nM (Teno et al., 1993), although it suffers from the same
lack of specificity as previous benzylamine derivatives
(Markwardt et al., 1968). b-Lactam analogues have also been
used to produce a number of serine protease inhibitors
(Konaklieva, 2002), including a series of KLK3 inhibitors
with inhibition in the nM range, although the specificity of
this inhibition was not evaluated (Adlington et al., 1997,
2001).
Recently, phage display has been used to identify a series
of KLK2 peptide inhibitors with inhibition constants in the
lower micromolar range and selectivity over a number of
tryptic serine proteases, including KLKB1 (Hekim et al.,
2006). The stability of these peptides was later improved by
head-to-tail cyclisation and/or internal disulfide bond for-
mation, without loss of potency (Pakkala et al., 2007). The
same group also produced three non-peptide KLK3 inhibitors
with inhibition in the nanomolar range by screening against
a library of small drug-like molecules (Koistinen et al.,
2008b). The development of these inhibitory peptides has
recently been reviewed (Koistinen et al., 2008a).
Small-molecule kallikrein inhibitors have not had the same
clinical success as bioscaffold-based inhibitors. However,
transition-state analogues are currently being investigated for
use as activity-based probes, utilising the platform initially
established for organophosphate peptide inhibitors (Liu et al.,
1999), which were developed to detect KLK6 (Oikonomo-
poulou et al., 2008). Clearly, the bioscaffold approach
and conventional small-molecule design techniques are
complementary.
Conclusions
There is increasing appreciation of the potential roles played
by the kallikrein proteases as regulators of human physiol-
ogy, as biomarkers in disease diagnosis and as points for
therapeutic intervention. With application of the strategies
we have discussed here, the next decade could see a blos-
soming of research in this area and the production of a new
generation of protease inhibitor drugs to rival the antiviral
protease inhibitors.
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